PitchSend

Investor Presentaiton

Jeuveau: Designed to Compete Clinically with the Market Leader Primary Endpoint Responder Rate Day 30 GLS = 0 or 1 Maximum Frown Investigator Assessment 100 87.2 90 82.8 80 70 60 50 40 30 20 10 4.2 0 Jeuveau n=235 TM Botox n=244 Placebo n=48 Safety Profile - Adverse Events All Related EU PIII EVB-003 Placebo Onabot Prabot 32.7% 41.9% 37.6% 4.1% 14.6% 15.5% Serious Adverse Effects Other AE's of Interest Drug Related • None Ptosis (related) Eyelid - Jeuveau 1.6%, Botox 0% Eyebrow - Jeuveau 0%, Botox 0.4% в 8 14

View entire presentation